Robert W. Baird Reiterates “Hold” Rating for Proteon Therapeutics, Inc. (PRTO)

Proteon Therapeutics, Inc. (NASDAQ:PRTO)‘s stock had its “hold” rating reissued by analysts at Robert W. Baird in a report released on Friday. They currently have a $2.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s price objective points to a potential upside of 8.11% from the company’s previous close.

Several other brokerages have also issued reports on PRTO. Zacks Investment Research lowered Proteon Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday. HC Wainwright reiterated a “hold” rating and set a $2.30 price objective on shares of Proteon Therapeutics in a research note on Wednesday. Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Finally, Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $6.13.

Shares of Proteon Therapeutics (PRTO) traded up $0.05 during trading hours on Friday, hitting $1.85. The company had a trading volume of 32,600 shares, compared to its average volume of 47,141. Proteon Therapeutics has a one year low of $1.10 and a one year high of $11.45.

TRADEMARK VIOLATION WARNING: “Robert W. Baird Reiterates “Hold” Rating for Proteon Therapeutics, Inc. (PRTO)” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at

A hedge fund recently raised its stake in Proteon Therapeutics stock. Pharmstandard International S.A. raised its holdings in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) by 43.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,667,907 shares of the biopharmaceutical company’s stock after acquiring an additional 502,563 shares during the quarter. Proteon Therapeutics makes up about 9.7% of Pharmstandard International S.A.’s investment portfolio, making the stock its 3rd biggest position. Pharmstandard International S.A. owned about 9,465,987.51% of Proteon Therapeutics worth $3,336,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 47.07% of the company’s stock.

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply